Sinovac Biotech's gross profit for the
six
months ended in Jun. 2023 was $-48.0 Mil. Sinovac Biotech's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was $-197.6 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Sinovac Biotech's gross profit for the
six
months ended in Jun. 2023 was $-48.0 Mil. Sinovac Biotech's Revenue for the
six
months ended in Jun. 2023 was $140.4 Mil. Therefore, Sinovac Biotech's Gross Margin % for the quarter that ended in Jun. 2023 was -34.19%.
Sinovac Biotech had a gross margin of -34.19% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage
During the past 13 years, the highestGross Margin % of Sinovac Biotech was 94.47%. The lowest was -46.96%. And the median was 81.11%.
Warning Sign:
Sinovac Biotech Ltd gross margin has been in long-term decline. The average rate of decline per year is -6.3%.
Sinovac Biotech Gross Profit Historical Data
The historical data trend for Sinovac Biotech's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sinovac Biotech's Gross Profit
For the Biotechnology subindustry, Sinovac Biotech's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinovac Biotech's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Gross Profit distribution charts can be found below:
* The bar in red indicates where Sinovac Biotech's Gross Profit falls into.
Sinovac Biotech Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Sinovac Biotech's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-197.6 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sinovac Biotech had a gross margin of -34.19% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage
Sinovac Biotech Gross Profit Related Terms
Thank you for viewing the detailed overview of Sinovac Biotech's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Sinovac Biotech (Sinovac Biotech) Business Description
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SVA has been successfully added to your 